Showing 3591-3600 of 9296 results for "".
- Lilly's Lebrikizumab Performs Well in Two Phase 3 AD Trialshttps://practicaldermatology.com/news/lillys-lebrikizumab-performs-well-in-two-phase-3-ad-trials/2460892/Eli Lilly and Company's lebrikizumab led to significant improvements with at least 75 percent skin clearance in more than half of people with moderate-to-severe atopic dermatitis (AD), according to top-line results from ADvocate 1 and ADvocate 2. All primary and all key secondary endpoints, includ…
- Etrasimod Performs Well in Phase Phase 2b Trial of Adult Atopic Dermatitishttps://practicaldermatology.com/news/etrasimod-performs-well-in-phase-phase-2b-trial-of-adult-atopic-dermatitis/2460761/Arena Pharmaceuticals, Inc.’s Etrasimod demonstrated statistical significance in both clinician and patient reported outcomes in atopic dermatitis, according to research presented at the American Academy of Dermatology VMX Experience. Etrasimod is an investigational, highly selective, once-daily, …
- Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in EBhttps://practicaldermatology.com/news/abeona-receives-fda-regenerative-medicine-advanced-therapy-designation-for-eb-101-gene-therapy-in-eb/2457908/The US Food and Drug Administration (FDA) granted the Regenerative Medicine Advanced Therapy (RMAT) designation to EB-101, Abeona Therapeutics Inc.’s gene-corrected autologous cell therapy product for patients with recessive dystrophic epidermolysis bullosa (RDEB). “EB-101 is an autologous gene-co…
- FDA Approves BMS's Opdivo as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Diseasehttps://practicaldermatology.com/news/fda-approves-bmss-opdivo-as-adjuvant-therapy-in-patients-with-completely-resected-melanoma-with-lymph-node-involvement-or-metastatic-disease/2457941/The FDA has approved Bristol-Myers Squibb Company's Opdivo (nivolumab) injection for intravenous use for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. The purpose of adjuvant therapy is to reduce the ris…
- Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in EBhttps://practicaldermatology.com/news/abeona-therapeutics-receives-fda-breakthrough-therapy-designation-for-eb-101-autologous-cell-therapy-in-eb/2458075/The U.S. Food and Drug Administration granted Breakthrough Therapy Designation status to the Abeona Therapeutics Inc.’s EB-101 gene therapy program for patients with Recessive Dystrophic Epidermolysis Bullosa. EB-101 is an autologous, ex-vivo gene-corrected cell therapy in which the COL7A1 gene is…
- Jeune Aesthetics Announces Positive Clinical Phase 1 Efficacy Results for KB301https://practicaldermatology.com/news/jeune-aesthetics-announces-positive-clinical-phase-1-efficacy-results-for-kb301/2461119/Aesthetics, Inc.’s KB301 demonstrated promise in proof-of-concept in the Phase 1 PEARL-1 study. Specifically, Cohort 2 of this trial evaluated KB301 for the improvement of fine lines and skin texture in the lower and upper cheek, and for improvement in skin thickness in the knee. KB301 is designe…
- Tremfya Reduces Fatigue in PsAhttps://practicaldermatology.com/news/tremfya-reduces-fatigue-in-psa/2460602/The IL-23 blocker Tremfya (guselkumab) improves fatigue in adult patients with active psoriatic arthritis (PsA) and this response is maintained through 52 weeks of active treatment, according to data from two Phase 3 clinical trials, DISCOVER-1 and DISCOVER-2. Tremfya improved fatigue during the p…
- DERM2019 Day 4: Contact Dermatitis, Dermoscopy Bootcamp, and Morehttps://practicaldermatology.com/news/derm2019-day-4-contact-dermatitis-dermoscopy-bootcamp-and-more/2460103/The last day of DERM2019 included a dermoscopy session and several other key presentations from Jennifer Stein, David Cohen, and Gilly Munavalli. Here’s a brief recap from some of those talks! Dermoscopy Bootcamp Presented by Jennifer Stein Recap by Jayme M. Heim MSN, FNP-BC, West Michigan Derm…
- Answered: Your Questions About Employee Management and COVID Risk Mitigationhttps://practicaldermatology.com/news/answered-your-questions-about-employee-management-and-covid-risk-mitigation/2460650/Can I require staff to get a vaccine in order to continue working? In many cases, vaccines can be required, says Josh Alloy, JD, Counsel at Arnold and Porter in Washington, DC, “although there are potential exceptions, and businesses should also consider other ways of incentivizing staff to be vac…
- Practical Considerations in Pediatric Alopeciahttps://practicaldermatology.com/news/practical-considerations-in-pediatric-alopecia/2461950/Hair loss in children encompasses a wide spectrum of conditions that may be congenital or acquired. Hair consists of the proteinaceous shaft and the root, anchored in the follicle, an involution of the epidermis.1 Newborn follicles produce soft lanugo hair, which is replaced by downy, fine vellus h…